TickerTalks
Browse all tickers →
TickerTalks›$IDYA
IDIDYA

IDEAYA Biosciences, Inc.

$IDYA·$3.7B·Biotechnology·Healthcare
$38.41-0.5%YTD+12.0%1Y+46.5%
Price updated 3h ago·X counts updated 5d ago
IDIDYA
$IDYAIDEAYA Biosciences, Inc.
$38.41-0.52%29 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $IDYA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

29X posts · last 7 days
Sep 1Sep 14
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $IDYA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-07

IDEAYA had a successful FDA Type C meeting for IDE849 (DLL3 TOP1 ADC), targeting a Phase 3 registrational trial for ES-SCLC monotherapy with accelerated + full approval path. Buyers added at $39.50 (average $33.82), Citizens reiterated Outperform at $42, and management is running healthcare conferences plus R&D Day 9/16.

Read what X is saying about $IDYA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $IDYA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-09-19

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

IDEAYA Biosciences coiled — DLL3 TOP1 ADC Type C FDA meeting successful, R&D Day Sept 16.

IDEAYA Biosciences is a precision-oncology synthetic-lethality biotech — the pipeline includes IDE849 (DLL3 TOP1 ADC), IDE397 (MTAP-deleted cancers), and multiple partnered programs. The equity is coiling with specific clinical catalysts.

  • The FDA Type C meeting was a specific validation: successful IDE849 Type C meeting targeting Phase 3 registrational trial for extensive-stage small-cell lung cancer (ES-SCLC) monotherapy with accelerated + full approval path — that's a specific and material regulatory milestone.
  • The valuation is where clinical-catalyst-biotech works: 11.3x TTM sales on -19% ROIC — this is priced against specific 2026-2028 clinical readouts plus partnered-royalty income, and the recent Q2 revenue $8.9M (+35%) shows early commercial-scale activity.
  • The R&D Day 9/16 was the specific near-term catalyst: management running healthcare conferences plus the R&D Day, with Citizens reiterating Outperform at $42 PT — that's specific sell-side confirmation of the pipeline strategy.

Nov 9 Q3 earnings is the referee. A confirming beat plus specific IDE849 Phase 3 trial-design commentary extends the coil upward; a soft partnered-program comment or a specific clinical-timing miss resets. Watch $34 as coil support and $45 as the level that continues the acceleration. The specialty-oncology cohort (IDYA, RXRX, ERAS) sets direction on macro-oncology days.

Agrees with X sentimentThe IDE849 FDA Type C meeting success and accelerated + full approval path framing captures the specific regulatory-milestone catalyst correctly. The Citizens Outperform reiteration at $42 PT is real sell-side alignment.

What to watch: Nov 9 Q3 earnings — IDE849 Phase 3 trial-design commentary, partnered-program revenue, and any specific IDE397 clinical update. Watch $34 coil support.

On the calendar: 2026-11-09 — Q3 earnings

Read the AI verdict on $IDYA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Precision oncology biotech exploiting synthetic lethality to develop targeted therapies including POLQ and MAT2A inhibitors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IDYA.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $IDYA

Partial — synthetic lethality-driven oncology drugs (POLQ inhibitor iniparib, MAT2A inhibitor IDE397) benefit from the precision-oncology re-rating; Gilead collaboration partnership adds validation but Phase 1/2 stage limits near-term revenue leverage.

Top industry ETF

$IBBiShares Biotechnology ETF
+22.1%YTD
+42.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-18.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-19.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-81.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
11.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-14.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-1.22$-1.06-15.1%
Q1 2026May 5, 2026$-1.11$-1.07-3.7%
Q4 2025Feb 17, 2026$-0.94$-0.95+1.2%
Q3 2025Nov 4, 2025$1.33$-0.95+240.6%
Next earningsMon, Nov 9·consensus EPS $-1.18

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$6.6M—82.6%-1655%$-1.11$-76.1M
Q4 FY25$10.9M+55.4%100%-870%$-0.94$-90.8M
Q3 FY25$207.8M—100%52.2%$1.35$142.2M
Q2 FY25$0———$-0.88$-63.1M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$38.4M$12.4M – $52.5M-$4.59-$5.24 – -$4.2211
FY27$115.5M$30.8M – $220.0M-$4.13-$5.21 – -$1.8410
FY28$254.8M$117.5M – $452.7M-$3.34-$4.32 – -$0.3312
FY29$567.2M$180.6M – $1.1B-$1.51-$3.33 – -$0.1710
FY30$1.0B$332.2M – $2.0B$1.42$0.16 – $3.116

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.3.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.77%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+13.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 87.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 7Ruiz Briseno AndresChief Accounting Officer9.6K sh$382K
+ 7 other (6 awards · 1 exempt) in window

See when $IDYA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 238-K — Item 5.07: Shareholder vote · Item 8.01: Other event
AI summary

Delaware 001-38915 47-4268251 disclosed voting results from its annual or special meeting. c. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026. Only stockholders of record as of the close of business on April ... Delaware 001-38915 47-4268251 disclosed: c. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026. Only stockholders of record as of the close of business on April 20, 2026, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of.

424B5Prospectus supplement (offering)Jun 9424B5
AI summary

IDEAYA Biosciences' final prospectus supplement for its June 2026 equity offering: 5,555,556 shares at $27.00 per share plus 5,555,576 pre-funded warrants at $26.9999 per warrant, for total gross proceeds of $300 million; underwriting discount of $1.62 per share; delivery June 10, 2026. Joint bookrunners: J.P. Morgan, Jefferies, TD Securities, UBS, and Cantor Fitzgerald, with an overallotment option for 1,666,669 additional shares. This approximately $282 million net raise funds IDEAYA's clinical development pipeline anchored by the uveal melanoma registrational study.

424B5Prospectus supplement (offering)Jun 8424B5
AI summary

IDEAYA Biosciences filed a preliminary (Subject to Completion) prospectus supplement on June 8, 2026 for a $300 million common stock and pre-funded warrants offering (exact share count and price to be determined by bookbuild), with an overallotment option for an additional $45 million. This is the draft form of the offering finalized on June 9, 2026 at $27.00 per share for total $300 million gross proceeds. No economic terms are locked in this preliminary filing.

3New insider — initial holdingsJun 53
AI summary

Theodora Ross, newly appointed Chief Development Officer at IDEAYA Biosciences (IDYA), filed a Form 3 on June 5, 2026 reporting no directly held common shares but disclosing 297,200 stock options at $31.90/share expiring February 26, 2036. The options vest 25% on the first anniversary of her February 23, 2026 commencement date and 1/48th monthly thereafter. Routine initial Section 16 beneficial ownership disclosure for a newly appointed executive officer.

8-KPress release / Reg FDJun 18-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

IDEAYA Biosciences and partner Servier presented complete Phase 2/3 OptimUM-02 registrational trial data at ASCO 2026 as a late-breaking oral presentation: 313 patients with first-line HLA*A2:01-negative metastatic uveal melanoma were randomized 2:1 to darovasertib plus crizotinib versus investigator's choice immunotherapy. The primary endpoint of median progression-free survival by blinded central review showed a statistically significant benefit over immunotherapy, supporting a potential FDA accelerated approval submission for the first targeted therapy in this indication.

424B5Prospectus supplement (offering)May 5424B5
AI summary

IDEAYA Biosciences filed a 424B5 prospectus supplement on May 5, 2026 for its existing ATM offering under the Sales Agreement with Jefferies LLC (originally dated January 19, 2024), covering the remaining approximately $156.6 million of aggregate gross proceeds still available under the $350 million total ATM capacity. Of the $350 million total, $193.4 million had already been raised under a prior prospectus supplement; the updated 424B5 is filed against IDEAYA's new S-3ASR shelf (JOB 89) following the termination of the prior S-3. IDYA's May 1, 2026 closing price was $28.19 per share.

S-3ASRAuto-shelf registrationMay 5S-3ASR
AI summary

IDEAYA Biosciences filed a new automatic shelf registration statement (S-3ASR) on May 5, 2026 to replace its prior S-3 (filed June 26, 2023 and expiring June 26, 2026); the new shelf covers common stock, preferred stock, debt securities, warrants, and units and is effective immediately upon filing as a large accelerated filer. Pursuant to Rule 415(a)(6), the prior registration statement was simultaneously terminated. The companion 424B5 ATM prospectus supplement (JOB 88) transfers the remaining approximately $156.6 million ATM capacity to this new shelf.

+ 16 other (5 routine 8-Ks · 4 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYAdefenseworld.net·1d agoIDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com·9d agoIDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanomaprnewswire.com·10d agoIDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferencesprnewswire.com·18d agoIDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancerprnewswire.com·19d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $IDYA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport